The investment from the Alzheimer’s Disease Drug Discovery Foundation (ADDF) is aimed at supporting the development of Coya 302, a potential treatment for frontotemporal dementia (FTD).
Coya Therapeutics receives $5 million investment from Alzheimer’s Disease Drug Discovery Foundation
Leave a comment
